General practitioner practice-based pharmacist input to medicines optimisation in the UK: pragmatic, multicenter, randomised, controlled trial

Table 2 Medication appropriateness index (MAI) scores; ITT analysis

Outcome measures	Control			Intervention			p value
	n = 60 (48.8%)*			n = 63 (51.2%)*
	Baseline	End	Difference^a	Baseline	End	Difference^a
Number of medications scored (total)	620	601		628	602
Mean ± SD^#	10.3 ± 3.6	10.0 ± 3.9		10.0 ± 3.8	9.6 ± 3.9
Median [IQR]^#	10 [7.3–12.0]	10 [6.3–12.0]		9 [7.0–12.0]	9 [7.0–11.0]
Summated MAI score per patient, mean ± SD	9.1 ± 7.3	9.1 ± 8.5	0.0 ± 4.0	9.6 ± 7.6	7.2 ± 8.1	2.4 ± 4.8	0.879^b < 0.001^c 0.001^d
Median [IQR]	8 [313]	7 [312]	0 [0–0]	8 [4–13]	5 [0–11]	0 [0–5]	0.879^b < 0.001^c 0.001^d

Bold values denote statistical significance at the p < 0.05 level
*Random sample (random.org) of one-third of the total sample in every practice, ^#Medications per patient
^aCalculated as MAI score at baseline – MAI score at end of study
^bWilcoxon signed rank test in control group, between baseline and end of study
^cWilcoxon signed rank test in intervention group, between baseline and end of study
^dMann–Whitney U test between groups at end of study for MAI difference

ISSN: 2052-3211